Drug Profile
Research programme: anti-infectives - GlaxoSmithKline/Valneva
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Intercell
- Developer Valneva
- Class Antibodies; Bacterial vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections; Viral infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Austria
- 04 Nov 2017 No recent reports of development identified for preclinical development in Viral-infections(Prevention) in Austria
- 28 May 2013 Intercell has merged with Vivalis to form Valneva